The Filing Desk

Lipocine vs Oramed Pharmaceuticals

Lipocine LPCN · Oramed Pharmaceuticals ORMP · Pharmaceuticals

Lipocine reported revenue of $2 million in fiscal 2025, about the same as Oramed Pharmaceuticals' $2 million in fiscal 2025. Lipocine had an operating margin of -524.7%, against -754.4% at Oramed Pharmaceuticals.

Side by side

LipocineOramed Pharmaceuticals
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$2M$2M
Revenue growth−82.3%—
Revenue growth a year, last 5 years—−5.8%
Gross margin—0.7%
Operating margin−524.7%−754.4%
Net margin−487.1%3,202.5%
Free cash flow—−$9M
Free cash flow margin—−457.7%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$5M
Change in diluted share count5.3%3.8%
Last close$1.50$3.69
P/E at the last close—1.1×
Insider trades, last 12 months—sold $941,874
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
LipocineOramed Pharmaceuticals
Operating margin
Percent of revenue
LipocineOramed Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
LipocineOramed Pharmaceuticals

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Lipocine and Oramed Pharmaceuticals pages.